Division of Rheumatology/Immunology/Allergy, Department of Internal Medicine, Tri Service, General Hospital, National Defense Medical Centre, Taipei 11490, Taiwan.
Division of Chest Medicine, Department of Medicine, Cheng Hsin General Hospital, Taipei 11220, Taiwan.
Genes (Basel). 2020 Jun 26;11(6):705. doi: 10.3390/genes11060705.
So far, numerous meta-analyses have been published regarding the correlation between peroxisome proliferator-activated receptor gamma (PPARG) proline 12 alanine (Pro12Ala) gene polymorphism and chronic kidney disease (CKD); however, the results appear to be contradictory. Hence, this study is formulated with the objective of using existing meta-analysis data together with our research population to study the correlation between PPARG Pro12Ala gene polymorphism and CKD and evaluate whether an accurate result can be obtained.
First, literature related to CKD and PPARG Pro12Ala available on the PubMed and EMBASE databases up to December 2016 was gathered from 20 publications. Then, the gathered results were combined with our case-control study of 1693 enrolled subjects and a trial sequential analysis (TSA) was performed to verify existing evidence and determine whether a firm conclusion can be drawn.
The TSA results showed that the cumulative sample size for the Asian sample was 6078 and was sufficient to support a definite result. The results of this study confirmed that there is no obvious correlation between PPARG Pro12Ala and CKD for Asians (OR = 0.82 (95% CI = 0.66-1.02), I = 63.1%), but this was not confirmed for Caucasians. Furthermore, the case-control sample in our study was shown to be the key for reaching this conclusion.
The meta-analysis results of this study suggest no significant correlation between PPARG Pro12Ala gene polymorphism and CKD for Asians after adding our samples, but not for Caucasian.
到目前为止，已有大量荟萃分析研究过过氧化物酶体增殖物激活受体γ（PPARG）脯氨酸 12 丙氨酸（Pro12Ala）基因多态性与慢性肾脏病（CKD）之间的相关性，但结果似乎相互矛盾。因此，本研究旨在使用现有的荟萃分析数据和我们的研究人群来研究 PPARG Pro12Ala 基因多态性与 CKD 的相关性，并评估是否可以获得准确的结果。
首先，从 20 篇文献中收集了截止到 2016 年 12 月发表在 PubMed 和 EMBASE 数据库中与 CKD 和 PPARG Pro12Ala 相关的文献。然后，将收集到的结果与我们的 1693 名入组患者的病例对照研究相结合，并进行试验序贯分析（TSA）以验证现有证据并确定是否可以得出确定的结论。
TSA 结果表明，亚洲人群的累积样本量为 6078，足以支持明确的结果。本研究的结果证实，PPARG Pro12Ala 与亚洲人群的 CKD 之间没有明显相关性（OR = 0.82（95% CI = 0.66-1.02），I = 63.1%），但对高加索人群则没有证实。此外，我们的研究中的病例对照样本是得出这一结论的关键。
本研究的荟萃分析结果表明，在加入我们的样本后，亚洲人群的 PPARG Pro12Ala 基因多态性与 CKD 之间没有明显相关性，但对高加索人群则没有。
